Making another run at cancer, S.F. biotech corrects course after clinical trial failure

Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial.

Click to view original post